-+ 0.00%
-+ 0.00%
-+ 0.00%

Delcath Systems flags Phase 2 study sequencing HEPZATO liver perfusion with tebentafusp in metastatic uveal melanoma

PUBT·05/26/2026 20:01:52
Listen to the news
Delcath Systems flags Phase 2 study sequencing HEPZATO liver perfusion with tebentafusp in metastatic uveal melanoma
  • Delcath Systems flagged two investigator-initiated trials-in-progress abstracts published May 21, 2026, scheduled for poster presentation at ASCO 2026.
  • One Phase 2 study is testing HEPZATO liver-directed therapy followed by tebentafusp in liver-dominant metastatic uveal melanoma.
  • A separate Phase 1b/2 study is evaluating HEPZATO combined with nivolumab-relatlimab as a first-line approach in non-uveal melanoma with liver metastases.
  • No efficacy results were reported; the programs are designed to assess clinical benefit, safety, and durability of response.
  • Enrollment began in November 2025 for the Phase 2 trial, January 2026 for the Phase 1b/2 trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delcath Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605261601BIZWIRE_USPR_____20260526_BW453584) on May 26, 2026, and is solely responsible for the information contained therein.